Cardiovascular Diseases Clinical Trial
— COLCATOfficial title:
Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery: Prospective, Randomized, Triple-blinded, Placebo-controlled, Multi-centre Study
Perioperative myocardial injury/infarction (PMI) and major adverse cardiovascular events (MACE) are common causes of morbidity and mortality in patients at increased cardiovascular risk undergoing non-cardiac surgery. However, research in recent years has yielded limited preventive and therapeutic measures for PMI/MACE. Recent studies in patients with chronic and acute coronary artery disease have shown that colchicine administration can reduce the risk of cardiovascular events. These encouraging results in non-surgical patients ask for a similar investigation in patients undergoing major non-cardiac surgery. The aim of the proposed study is to investigate the effects of perioperative colchicine administration on the incidence of PMI/MACE.
Status | Not yet recruiting |
Enrollment | 880 |
Est. completion date | September 30, 2028 |
Est. primary completion date | September 30, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years and older |
Eligibility | Inclusion Criteria: undergoing major non-cardiac surgery in general anaesthesia will be included. Major non-cardiac surgery is defined as: - vascular surgery (with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies) - intraperitoneal surgery - intrathoracic surgery - major orthopaedic surgery (spinal surgery or joint replacement surgery) - at cardiovascular risk, defined as meeting at least 1 of the following 6 criteria: - preoperative n-terminal pro brain natriuretic peptide (NT-proBNP) = 200 ng/l - history of coronary artery disease - history of peripheral vascular disease - history of stroke - undergoing major vascular surgery, with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies - fulfilment of any 3 of the 8 following criteria: - undergoing major surgery (intrathoracic, intraperitoneal or supra-inguinal vascular surgery) - any history of congestive heart failure or history of pulmonary oedema - anamnestic transient ischemic attack (TIA) - diabetes under treatment with either oral antidiabetic agent or insulin - age > 70 years - history of hypertension - serum creatinine > 175 mumol/l or calculated creatinine clearance < 60 ml/min/1.73m2 (cockcroft gault) - history of smoking within 2 years of surgery - planned surgical time = 90 minutes - planned postoperative hospital stay at least 1 night Exclusion Criteria: - no written consent - inclusion in other clinical trial with direct impact on perioperative medication - previously reported side effects or reported intolerance from colchicine (e.g., allergic reaction or significant sensitivity to colchicine or an auxiliary substance of the IMP) - pregnancy or planned pregnancy and/or breast feeding - clinically significant history of drug or alcohol abuse within the last year - very severe frailty (= 8 clinical frailty scale) - patient with inflammatory bowel disease (e.g., Morbus Crohn or Colitis ulcerosa) - patient taking colchicine for other indications (e.g., familial Mediterranean fever, gout) - severe renal impairment (eGFR < 30 ml min -1 1.73 m2 -1) or end-stage renal disease with indication for haemodialysis - history of solid organ or bone marrow transplantation - systemic immune-suppression (medication (steroids >30mg cortisol-equivalent per day, tacrolimus etc...) or disease (e.g., myelodysplastic syndrome) - severe hepatic impairment with history of cirrhosis - chronic active hepatitis or functional disorders defined as alanine aminotransferase greater than three times the upper limit of normal - anticipated post-operative administration of CYP3A4 metabolized substances like cyclosporine, ketoconazole, clarithromycin, verapamil, quinidine, diltiazem or ritonavir - Any other condition that the investigator would consider a risk to the patient if the latter were to participate in the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cantonal Hospital of St. Gallen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Gastrointestinal adverse events | Proportion of patients developing gastrointestinal side effects as: diarrhoea, abdominal cramping, abdominal pain, vomiting, nausea after the intervention | From the first intake of the study drug until 72 hours after the last intake of the study drug (i.e., postoperative day 6) or until discharge from the hospital, whatever comes first | |
Primary | Perioperative Myocardial Injury/Infarction | Proportion of patients developing PMI in the peri- postoperative course. The primary outcome is a composite of PMI and 30-day MACE. PMI is defined as an absolute perioperative rise in hs-cTnT of = 14 ng/l above preoperative values (or between two postoperative measurements, if preoperative hs-cTnT is missing). | until postoperative day 4 | |
Primary | Major Adverse Cardiovascular Events | Proportion of patients developing MACE in the peri- postoperative course. MACE is defined as a composite of any of the following within 30 days following surgery:
Acute coronary syndrome New/worsening congestive heart failure Coronary revascularization Stroke All-cause mortality Cardiovascular death |
until postoperative day 30 | |
Secondary | New onset Atrial fibrillation | Proportion of patients developing new-onset atrial fibrillation in the peri- postoperative course. The time frame includes the time from beginning of surgery (ECG monitoring in the peri- and early postoperative course on postoperative care unit/intensive care unit) until the date of first documented occurrence of atrial fibrillation (perioperative monitoring by daily nurse-controlled pulse examination, verified by an ECG in case of suspected arrhythmia/atrial fibrillation). These monitoring procedures take place until the discharge from the hospital. | From beginning of surgery/surgical procedures until the date of first documented occurrence or until postoperative day 30/discharge from hospital, whatever comes first | |
Secondary | postoperative high sensitive cardiac Troponin T concentrations | Comparison of postoperative hs-cTnT concentrations (maximal increase from individual baseline & the area under the curve) until postoperative day 4 between the study groups | until postoperative day 4 | |
Secondary | long term cardiovascular outcome | Proportion of patients developing MACE in regard of long term cardiovascular outcome after surgery.1-year composite endpoint of MACE (composite of acute coronary syndrome, new or worsening congestive heart failure, coronary revascularization, stroke, all-cause mortality and cardiovascular mortality) as a marker of long-term postoperative outcome. | until 1 year after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|